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In Brief
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metabolic effects in lean mice. They show
that these cells are seeded from the
thymus soon after birth and that their
accumulation depends on local antigens
and mediators, notably interleukin-33.
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A unique population of Foxp3+CD4+ regulatory T
(Treg) cells, with a distinct transcriptome and anti-
gen-receptor repertoire, resides in visceral adipose
tissue (VAT) of lean individuals. These cells regulate
local inflammation and both local and systemic
metabolic indices. Here we focus on expansion of
the VAT Treg compartment in aging lean mice—
assessing these cells’ phenotypic conversion from
conventional CD4+ T cells, influx from lymphoid or-
gans, and local population dynamics. Our findings
establish that the VAT Treg compartment is seeded
from thymocytes generated during the first weeks
of life and expands beyond 10 weeks of age due to
indolent proliferation, of certain clones in particular,
coupled with enhanced survival. Accumulation of
VAT Tregs depends on the antigen(s) presented
by MHC class-II molecules and soluble mediators,
notably interleukin(IL)-33. Addressing such factors
therapeutically promises novel approaches for har-
nessing Tregs to stem the growing epidemic of
obesity and consequent metabolic abnormalities.
INTRODUCTION
Visceral adipose tissue (VAT), notably the epididymal fat depot in
mice and omental depot in humans, is a site where metabolic
and immunologic processes interplay (Osborn and Olefsky,
2012; Mathis, 2013). The epididymal fat of lean mice is main-
tained in an anti-inflammatory state, kept in check by cells of
both the innate and adaptive immune systems, notably anti-in-
flammatory macrophages (MFs) and regulatory T (Treg) cells.
With nutrient overload, and the consequent onset of obesity,
this fat depot takes on a pro-inflammatory tenor, hosting a vari-
ety of innate and adaptive effector-cell types, such as neutro-
phils, pro-inflammatory MFs, CD8+ T lymphocytes, and T helperC(Th)1 cells. Given its inaccessibility, few studies have been done
on human omental fat, but some of the same immunocyte types
infiltrate this depot, notably MFs and Tregs, and this depot has
been the one most frequently associated with metabolic abnor-
malities. The anti-/pro-inflammatory balance in VAT is a critical
determinant of metabolic health, its dysregulation promoting in-
sulin resistance, type-2 diabetes, cardiovascular disorders, and
fatty liver.
Foxp3+CD4+ Treg cells are critical regulators of the inflamma-
tory state of murine VAT (Feuerer et al., 2009), perhaps not
surprising given that this lymphocyte subset controls most
types of immune responses (Josefowicz et al., 2012a). In lean
mice, visceral adipose depots harbor a population of Treg cells
very different from standard lymphoid tissue Tregs according to
a number of criteria. The fractional representation of VAT Tregs
(40%–80% of CD4+ T cells) is unusually high, rising well above
that of the circulating Treg pool (5%–15%). In addition, the tran-
scriptome of VAT Tregs from lean mice is distinct from that of
their lymphoid tissue counterparts, showing enrichment in tran-
scripts encoding certain chemokine receptors, (e.g., CCR1 and
CCR2), a few cytokines (e.g., unusually high levels of IL-10),
and a set of proteins involved in lipid metabolism (e.g., CD36,
Dgat1, and Ldlr). Lastly, adipose tissue and lymphoid tissue
Tregs display distinct repertoires of antigen-specific receptors
(T cell receptors [TCRs]). Obesity is accompanied by a striking
drop in the population of Treg cells in VAT, but not elsewhere,
and systemic reduction or augmentation of Tregs increases
or decreases adipose tissue inflammation and insulin resis-
tance, respectively (Feuerer et al., 2009; Eller et al., 2011),
arguing for a significant role for Treg cells in regulating meta-
bolic processes.
A major determinant of the VAT Treg gene expression signa-
ture in lean mice is a transcription factor important in the differ-
entiation and function of adipocytes, PPAR-g (Cipolletta et al.,
2012). Treg-specific ablation of Pparg resulted in depletion of
VAT, but not lymphoid tissue, Treg cells in mice fed a normal
diet (ND). Conversely, injection of the PPARg agonist pioglita-
zone into mice maintained on a high-fat diet (HFD), and thereby
impoverished in VAT Treg cells, greatly expanded the VAT, but
not lymphoid tissue, Treg population. Interestingly, many of theell Metabolism 21, 543–557, April 7, 2015 ª2015 Elsevier Inc. 543
well-known insulin-sensitizing effects of pioglitazone were blunt-
ed in mice lacking PPARg specifically in Treg cells.
These findings establish the importance of the VAT Treg
compartment in regulating local and systemic metabolic pro-
cesses but leave open the question of how this unique popula-
tion accumulates in lean individuals. We previously reported
that expansion of the VAT Treg pool in lean mice becomes
noticeable at 10–15weeks of age in ourmouse colony and peaks
at 20–25 weeks (Feuerer et al., 2009). Here we explore three
potential explanations for this accumulation: Treg phenotypic
conversion from conventional CD4+ T (Tconv) cells, influx of
Treg immigrants from the lymphoid organs, and local dynamics
of the VAT Treg population.
RESULTS
No Evidence of VAT Treg Conversion from Tconv Cells
Most Foxp3+CD4+ Treg cells are exported as such from the
thymus (and are termed tTregs). However, they can also be
generated in the periphery (pTregs) or in vitro (iTregs) by conver-
sion from Foxp3CD4+ Tconv cells; for example, in the presence
of transforming growth factor (TGF)-b. pTreg cells, notably those
residing in the intestinal lamina propria (Josefowicz et al., 2012b)
and placenta (Samstein et al., 2012), can make an important
contribution to the regulation of immune responses. Our previ-
ously reported sequencing data, discerning no overlap between
the TCR repertoires of VAT Treg cells and VAT or lymphoid tissue
Tconv cells in a mouse line engineered to express a drastically
reduced set of Tcra and Tcrb gene segments, argued against a
substantial population of converted VAT Tregs (Feuerer et al.,
2009). However, given the (overly) simplified model employed
in those studies, it was important to extend this conclusion to
a normal setting.
First, we examined the expression of markers purported to
distinguish between tTregs and pTregs, namely Helios and Neu-
ropilin (Nrp)-1 (Thornton et al., 2010; Weiss et al., 2012). These
are not perfect markers, but in general, pTregs have a Helio-
sloNrp-1lo phenotype while tTregs express high levels of both
proteins. Most Treg cells in VAT, as in lymphoid tissues, had a
HelioshiNrp-1hi phenotype; in fact, the fraction of Helios+ Tregs
in VAT was even higher than that in the spleen and lymph nodes
(LNs), approaching 100% (Figures 1A and 1B). These findings
held at both early and late stages of VAT Treg cell accumulation
in C57BL/6 (B6) mice (i.e., at both 15 and > 25 weeks of age).
Second, we searched for signs of Tconv/Treg phenotypic
conversion in the transcriptome of VAT Treg cells. Converted
Treg gene expression signatures were derived from multiple
well-studied in vivo and in vitro models: Tconv/Treg conver-
sion by (1) low-dose administration of antigen (influenza hemag-
glutinin [HA] peptide) through delivery to dendritic cells (DCs) as
a fusion with the monoclonal antibody (mAb) DEC205; (2) trans-
fer of naive Tconv cells into lymphopenic Rag-deficient mice,
thereby inducing homeostatic proliferation; and (3) activation of
cultured Tconv cells in the presence of IL-2 and TGF-b. Microar-
ray data on pTregs and iTregs generated in these models and on
VAT and control LN Treg cells have been reported previously
(Feuerer et al., 2010; Cipolletta et al., 2012); details on refinement
of the pTreg and iTreg ‘‘up’’ and ‘‘down’’ signatures can be found
in the Supplemental Experimental Procedures, as exemplified in544 Cell Metabolism 21, 543–557, April 7, 2015 ª2015 Elsevier Inc.Figure S1. Superimposition of these signatures onto volcano
plots comparing the transcriptomes of VAT and LN Treg cells
from >25-week-old B6 mice revealed no significant over- or un-
der-representation in VAT Tregs (Figure 1C), arguing against a
substantial pTreg contribution to this compartment. Similar re-
sults were obtained with VAT and LN Treg data from 5- and
14-week-old mice (not shown).
Third, we performed a transfer experiment to test directly
whether Tconv cells could turn on Foxp3 expression to become
VAT Tregs. Five million Tconv cells (GFPCD4+CD45.1+) were
sorted from spleens of 8-week-old Foxp3iGFP reporter mice
and were transferred intravenously (iv) into lean 20-week-old
CD45.2+ congenic recipients. (By-far-insufficient numbers pre-
cluded the use of VAT Tconv donor cells). Four weeks later, we
consistently saw a small population of donor-derived Treg cells
(GFP+CD4+CD45.1+) in the spleen and LNs but did not detect
them in VAT of any of the nine mice examined in multiple inde-
pendent experiments; we did, however, find donor-derived
Tconv cells (GFPCD4+CD45.1+) (Figure 1D).
Thus, none of our current or past data provide evidence of
VAT Treg conversion from Foxp3CD4+ Tconv cells. It might
be worth mentioning that we could not use the pTreg-deficient
CNS1mutantmouse line of Rudensky and colleagues to address
this issue because the Treg cells in those animals express a
Foxp3-GFP fusion protein that inhibits their accumulation in
VAT (Zheng et al., 2010; Darce et al., 2012) (data not shown).
Little Contribution of Circulating Tregs to the VAT
Compartment of Lean Mice
Another potential explanation for VAT Treg accumulation in older
mice is that around 10 weeks of age VAT becomes more attrac-
tive to circulating Treg cells, which install there and undergo
phenotypic adaptations. Therefore, we performed a series of
experiments to assess the ability of Treg cells to migrate from
the blood and peripheral lymphoid organs to VAT. A classical
approach to address such an issue is by means of transfer ex-
periments. A million GFP+ splenic Treg cells were isolated from
8- to 10-week-old CD45.1+Foxp3iGFP donors and were iv in-
jected into 20-week-old CD45.2+ recipients. 4 weeks later, the
contribution of donor Tregs to the spleen, LN, and VAT Treg
compartments was assessed. While CD45.1+ cells were readily
detectable in the lymphoid organs, making up about 0.5% of
the Treg population, significantly fewer were found in VAT (Fig-
ure 2A)—and most importantly, clearly not more.
Another, less invasive, approachmade use of Kaede/B6 trans-
genic mice, which express a photoconvertible (green/red) re-
porter in all cells under the dictates of b-actin gene promoter/
enhancer elements (Tomura et al., 2008). Immunocytes present
at a designated location can be innocuously photoconverted
by applying violet light transcutaneously, and their migration
can then be monitored for up to 2 weeks by ex vivo cytofluorim-
etry or fluorescence microscopy. We exposed cervical LNs
(CLNs) to violet light, monitored the egress of CD4+ T cell sub-
sets from that site, and followed their immigration over the next
72 hr into VAT versus pooled axial and inguinal LNs (A/ILNS),
the latter sites reflective of steady-state circulation, and so
used to calculate a ‘‘migration-ratio’’ that permits ready compar-
ison of migration to a designated site vis-a`-vis the general circu-
lation (Figure 2B). Consistent with our previous findings (Morton
A B 
D
C
Figure 1. No Evidence of VAT Treg Conversion from Tconv Cells
(A and B)Marker expression. Left panels: representative cytofluorometric dot plots of Helios (A) or Nrp-1 (B) expression in CD4+ T cell compartments of mice 15 or
>25 weeks of age. Right panels: corresponding summary data pooled from two independent experiments.
(C) Transcriptome analysis. FC versus p value plots comparing transcriptomes of VAT and LN Tregs isolated from 30-week-old mice (in triplicate). The indicated
signatures, derived as detailed in the Supplemental Experimental Procedures, were overlain on each plot. p values generated using the chi-square test.
(D) Transfer studies. Foxp3 Tconv cells from pooled spleen and LNs of CD45.1+Foxp3iGFP donors were iv transferred into CD45.2+Foxp3iGFP recipients, and
analyzed 4 weeks later. Left panels: representative flow cytometry plots. Summary data for donor Treg percentage (center panels) and number (right) are also
presented. Pooled data from three independent experiments. Mean ± SD.et al., 2014), Tconv cells exited the CLNs more rapidly than did
Treg cells (Figure 2C, left panel). In most mice, both Tconv and
Treg cells migrated substantially less effectively to VAT than to
lymphoid tissue (set at 1) (Figure 2C, right panel). This finding
was true whether we looked early (16 weeks of age) or late
(24 weeks) in the VAT Treg expansion phase (data not shown).
For a longer-term view, we turned to parabiosis experiments.
8-week-old B6.CD45.1 and B6.CD45.2 mice were conjoined,
and the chimerism of various T cell compartments was examined
4 or 6 weeks later (Figure 2D). Admixture of the spleen Treg pop-
ulation approached 50:50 after 4 weeks of parabiosis (40%), and
this mix was not significantly different 2 weeks later (43%).
Chimerism of the VAT Treg compartment was low at both time
points (17% and 24%), the values clearly diverging from their
spleen counterparts. Later parabiosis experiments revealed
that the majority of partner-derived Foxp3+CD4+ cells found in
VAT were circulating lymphoid-tissue-type Tregs, as they didCnot express typical VAT Treg markers (e.g., Gata3 and Klrg1) (Ci-
polletta et al., 2012) (data not shown).
Micro-Expansions of VAT Treg Clones
Next, we explored the dynamics of the Treg population residing
in VAT. Its accumulation could, in theory, reflect increased prolif-
eration or slower turnover vis-a`-vis lymphoid tissue Treg popula-
tions, or both. Proliferation was studied by quantifying incorpora-
tion of the nucleoside analog 5-ethynyl-20-deoxyuridine (EdU)
and by staining for Ki67, a marker for cycling cells. A 4 hr in vivo
pulse of EdU revealed a small population of dividing VAT Treg
cells, similar to what was found for splenic Tregs—while there
were significantly more (though still few) dividing cells in VAT at
15 to 16 weeks of age, this difference did not hold in older
mice (Figure 3A). Significantly more Treg than Tconv cells were
dividing in both spleen and VAT in both age groups. Ki67 stain-
ing, which labels cells at all but the Go phase of the cell cycle,ell Metabolism 21, 543–557, April 7, 2015 ª2015 Elsevier Inc. 545
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Figure 2. Little Contribution of Circulating Tregs to the VAT Compartment of Lean Mice
(A) Transfer studies. Foxp3+CD4+ Tregs were sorted from pooled spleen and LNs of CD45.1 Foxp3iGFP donors and iv transferred into CD45.2 Foxp3iGFP re-
cipients, and organs were analyzed 4 weeks later. Left panels: representative flow cytometry plots; right panels: summary data pooled from three independent
experiments.
(B) Photoconversion experiments. Experimental set-up and representative flow cytometry plots of CD4+ T cells isolated from the designated tissues immediately
after (left panels) and 24, 48, or 72 hr after (right panels) photoconversion. CLN, cervical lymph node. A/ILN, pooled axial and inguinal lymph nodes; VAT, visceral
adipose tissue.
(C) Summary data for dynamics of the Kaede-red+ population. Left panel: rate of egress of Treg and Tconv cells labeled in the CLNs; right panel: migration ratios of
Treg and Tconv cells expressed as a ratio over the analogous populations migrating to A/ILNs.
(D) Parabiosis experiments. Chimerism of Tconv and Treg cells represented as the percent of donor-derived cells among total live cells of that type. For all panels
data, are from two to three independent experiments. Mean ± SD.confirmed the similar behaviors of splenic and VAT Treg cells
(Figure 3B). While substantially more Treg than Tconv cells
were cycling in the spleen, the difference was less evident
in VAT.
Cell turnover was examined by quantifying labeling by bromo-
deoxyuridine (BrdU), another nucleoside analog, during long-
term incorporation and a subsequent chase. The rate and extent
of BrdU labeling for spleen and VAT Treg cells were indistin-
guishable over the 5-week period of BrdU administration in the
drinking water; these parameters were also similar for VAT Tconv
cells (Figure 3C, left curves). However, the loss of BrdU labeling546 Cell Metabolism 21, 543–557, April 7, 2015 ª2015 Elsevier Inc.over the 5-week time period subsequent to its removal from the
drinking water revealed a substantially faster decay rate for
splenic than for VAT Tregs: a half-life of 10.8 days in the former
case and 24.5 days in the latter (Figure 3C, right curves). The
VAT Tconv cell population showed a half-life of 16.5 days in
the same experiment, indicating that slow turnover is not a char-
acteristic of all T cell populations residing in this adipose tissue
depot and explaining the rise in Treg percentage within the
CD4+ compartment over time.
The similarity in spleen and VAT Treg cycling rates might
have masked clonal expansions in response to antigen(s). We
previously reported that the VAT, but not lymphoid tissue, Treg
TCR repertoire included multiple repeats of particular a and b
chains, but these experiments employed a line of mice geneti-
cally engineered to minimize options for TCR variable (V) and
joining (J) segment usage (Feuerer et al., 2009), meaning that
we could not estimate the true frequency of TCR repeats.
Here, individual Treg cells from LN or VAT and Tconv cells
from VAT of >25-week-old B6 mice were sorted into 96-well
plates, and the sequences of their TCR-b and TCR-a comple-
mentarity-determining region(CDR)3s were determined. For
both TCR chains, LN Tregs showed few CDR3 repeats (Fig-
ure 3D, left pies); the slight increase over the near-zero we previ-
ously reported (Feuerer et al., 2009; Burzyn et al., 2013) most
likely reflects the advanced age of the mice in our current study.
However, VAT Treg cells were very different: all mice showed
numerous clonal expansions, rising to as high as 80% of the
sequences examined (Figure 3D, center pies). Each mouse
harbored multiple expanded clones, none of which were com-
mon to different mice, and no clone was shared between VAT
Treg cells and LN Treg or VAT Tconv cells. In contrast, VAT
Tconv cells showed a degree of clonal expansion only slightly
greater than that found for LN Tregs (Figure 3D, right pies). There
was a linear relationship between the frequency of repeated
CDR3s and the fraction of Tregs in the VAT CD4+ T cell compart-
ment (Figures 3E and 3F).
For both the TCR-a and -b chains, CDR3 lengths were indistin-
guishable for the repeated VAT and the LN Treg populations (Fig-
ure 3G). Interestingly, N-nucleotide addition was reduced in
repeated VAT Treg TCR-b, but not TCR-a, chains—notably, a
quarter of the clonally expanded Treg sequences had no N-nu-
cleotides at all, and fewer of them had N-additions of >3 nucle-
otides (Figure 3H). This finding suggests that the corresponding
cells differentiated around the time when terminal deoxynucleo-
tidyl transferase (TdT) is usually turned on (i.e., within a week
after birth) (Bogue et al., 1992). (Note that the TCR-a chain is usu-
ally rearranged days after the b chain.)
Early Seeding of VAT Tregs
On the basis of the TCR sequencing results, we hypothesized
that the VAT Treg compartment is seeded early on, in the
first weeks of life, followed by an indolent expansion—of
certain clones in particular. As a first test of this notion, we
thymectomized or sham-operated B6 mice at 3 to 4 or
13.5 weeks of age (prior to or early during the typical expan-
sion of the VAT Treg population, respectively), let them age
until 25 weeks old (the usual peak of accumulation), and
analyzed the Treg compartments by flow cytometry. There
was no significant reduction in the fraction or number of
Foxp3+CD4+ Treg cells in VAT of thymectomized versus
sham-operated animals, irrespective of the age at which sur-
gery was performed (Figure 4A). Neither was there a detect-
able loss when we focused on bona fide VAT Treg cells ex-
pressing Gata3 (Figure 4B). Thus, thymic output beyond
3 weeks of age was not required for establishment of a
robust VAT Treg compartment.
A complementary approach was to exploit B6.Foxp3DTR mice
to systemically ablate Treg cells at different ages and then
assess the degree to which the VAT Treg population could be re-
constituted from newly generated cells. B6.Foxp3DTR mice ofCvarious ages were depleted of Treg cells by two injections of
diphtheria toxin 1 day apart, a regimen known to effectively
deplete them without provoking autoimmune manifestations
(Feuerer et al., 2009); they were then left until 25 weeks old,
when reconstitution of the Treg compartments was assessed
by flow cytometry. When Treg cells were punctually ablated at
16/17 days or 3 weeks of age, VAT Tregs attained a normal fre-
quency and number by 25 weeks, if not slightly elevated ones
(Figure 4C). In contrast, the VAT Treg compartment was compro-
mised when punctual Treg ablation was performed later on, at 8
or 13 weeks of age. This finding was substantiated by focusing
on Gata3+ bona fide VAT Treg cells (Figure 4D). In contrast,
splenic Treg populations in the same mice did not show any
such deficiencies (Figure 4C).
VAT Treg Cells Depend on MHCII Molecules and
Associate with Myeloid Cells Expressing Them
The ready detection of VAT Treg clonal expansion (Feuerer et al.,
2009) (Figure 3D), coupled with the identification of TCRs with
the same CDR3 protein sequence specified by different nucleo-
tide sequences in mice with constrained TCR diversity (Feuerer
et al., 2009), suggested that VAT Tregs might be responding to
one or more adipose tissue antigens. Recognition of cognate an-
tigen/major histocompatibility complex (Ag/MHC) molecules on
the surface of local antigen-presenting cells (APCs) by T cells
is usually the major driver of their retention in tissues. We there-
fore sought to identify the class ofMHCmolecules recognized by
VAT Treg cells.
CD1d is a non-classical MHC-like molecule that specializes in
presenting lipid antigens to subsets of CD4+, CD8+, and double-
negative T cells (Adams and Luoma, 2013) and is, therefore, an
interesting candidate for presentation of Ags capable of stimu-
lating VAT Tregs, especially given that they can take up lipids
through surface-bound CD36 (Cipolletta et al., 2012). However,
we found that Cd1d-KO mice maintained on ND had a VAT
Treg compartment of typical size expressing normal levels of
Foxp3 (data not shown). (Conflicting data on this point appear
in the literature, as summarized in Mathis [2013].)
The next most likely possibility was that, like standard Treg
cells, VAT Tregs see Ag(s) in the context of MHC class-II
(MHCII) molecules. As anticipated (Cosgrove et al., 1991),
MHCII-deficient mice had reduced numbers of CD4+ T lympho-
cytes in the spleen, both Tconv and Treg cells (Figure 5A, left
panels). This dearth was true of VAT Treg cells as well (Fig-
ure 5A, middle panels), and few of the remaining VAT Tregs
expressed Gata3 (Figure 5A, right panels). Thus, Treg cells
residing in the visceral adipose depot are thymically selected
and/or peripherally maintained by interactions with APCs dis-
playing MHCII molecules.
To identify the relevant MHCII+ APCs, we turned to flow cy-
tometry and confocal microscopy. Cytofluorimetric analysis of
VAT from >25-week-old B6 mice revealed all MHCII-expressing
cells to be CD45+ (i.e., of the hematopoietic lineage) (Figure 5B).
(Note that in all of these analyses gates were rigorously set by
comparison with data from MHCII-KO mice.) Co-staining for
CD11b and CD11c split the CD45+ population into five major
subsets: I, CD11b+11chi MFs; II, CD11b+11clo MFs/monocytes;
III, CD11b+11c eosinophils; IV, CD11b11c lymphoid-type
cells; and V, CD11b11c+ DCs (Figure 5C). All cells withinell Metabolism 21, 543–557, April 7, 2015 ª2015 Elsevier Inc. 547
No EdU
control 15 wks >25 wks
VAT
Spleen
A
1.9
0.9
1.3
0.6
2.2
1.0
1.5
1.2
0.0
0.0
0.0
0.0
EdU
Fo
xp
3 
Gated on CD4+ T cells
BrdU incorporation 
d1 d7 d21 d35/d0 d14 d28 d3 d7 d15 d10 d3 
C
(BrdU in drinking water) BrdU dilution 
**
y=106.8e-0.031x
R2 = 0.88
Half-life: 24.5 days
y=106.5e-0.07x
R2 = 0.98
Half-life: 10.8 days
0 7 14 21 28
0
50
100
Time after BrdU (days)
%
 In
iti
al
 B
rd
U
+  
po
ol
0 7 14 21 28 35
0
20
40
60
80
100
BrdU in water (days)
%
 B
rd
U
+
******
***
VAT Tregs
Spleen Tregs
VAT Tconvs
VAT Tregs
Spleen Tregs
VAT Tconvs
B
0
10
20
30
40
50>25 wks
15 wks
%
 K
i6
7+
Treg Tconv
0
20
40
60
80
100
E
40 500 10 20 30
0
20
40
60
80
100
F
LN
Tregs
VAT
Tregs
VAT
Tconvs
%
 re
pe
at
ed
 T
C
R
s
% VAT Tregs of CD4+ cells
R2 = 0.72
p = 0.032
D
%
 re
pe
at
ed
 T
C
R
s
*
*
*
*
*
Spleen VAT Spleen VAT Spleen VAT Spleen VAT
>25 wks
15 wks
Treg Tconv
***
***
NS
*
0 
10 
20 
30 
40 
8 9 10 11 12 13 14 15 
CDR3
7 8 9 10 11 12 13 14 15 16 
CDR3
0 
10 
20 
30 
40 
%
 o
f s
eq
ue
nc
es
 
LN Treg  (n=271) Repeated VAT Treg  (n=45)
G
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
%
 o
f s
eq
ue
nc
es
# N-additions (nucleotides)
TCR   chain
TCR   chain
0 
10 
20 
30 
40 
0 
10 
20 
30 
40 
CDR3 length (amino acids)
H
LN Treg
78% 73%
35%
52% 70%
71%
n = 46 n = 51
n = 39
n = 53 n = 53
n = 41
4.0%
7.8%
8.7%
n = 50
n = 51
n = 46
5.4%
0.0%
3.1%
n = 74
n = 54
n = 65
VAT Treg VAT Tconv
p < 0.001
p = ns
1
2
3
4
5
%
  E
du
+ 
(legend on next page)
548 Cell Metabolism 21, 543–557, April 7, 2015 ª2015 Elsevier Inc.
Spleen
VAT
Thx
Sham BA
DTR+
DTRC
20
40
60
80
0
5
10
15
0
1
2
3
0
20
40
60
0
4
8
0
20
40
60
80
D
0
20
40
60
80
0
20
40
60
80
5
10
15
20
0
1
2
3
0
20
40
60
0
5
10
15
Age of thymectomy (weeks)
# 
Fo
xp
3+
 T
 c
el
ls
/o
rg
an
(x
10
-6
)
G
at
a3
+ F
ox
p3
+
T 
ce
lls
/g
rm
(x
10
-3
)
3-4 13.5 3-4 13.5
3-4 13.5
3-4 13.5 3-4 13.5 3-4 13.5
%
 F
ox
p3
+ 
of
 C
D
4+
T 
ce
lls
Spleen
VAT
%
 G
at
a3
+ F
ox
p3
+
of
 C
D
4+
 T
 c
el
ls
Age of Treg ablation
16/17d 3-4 wks 8 wks 13 wks
0
16/17d 3-4 wks 8 wks 13 wks 16/17d 3-4 wks 8 wks 13 wks
16/17d 3-4 wks 8 wks 13 wks 16/17d 3-4 wks 8 wks 13 wks 16/17d 3-4 wks 8 wks 13 wks
noitalbagerTfoegAnoitalbagerTfoegA
Thx
Sham
%
 F
ox
p3
+ 
of
 C
D
4+
T 
ce
lls
)skeew(ymotcemyhtfoegA)skeew(ymotcemyhtfoegA
%
 G
at
a3
+ F
ox
p3
+
of
 C
D
4+
 T
 c
el
ls
# 
Fo
xp
3+
 T
 c
el
ls
/g
m
(x
10
-3
)
# 
Fo
xp
3+
 T
 c
el
ls
/o
rg
an
(x
10
-6
)
# 
Fo
xp
3+
 T
 c
el
ls
/g
m
(x
10
-3
)
G
at
a3
+ F
ox
p3
+ 
T 
ce
lls
/g
m
(x
10
-3
)
DTR+
DTR
* *
* ***
* ***
***
Figure 4. Early Seeding of VAT Tregs from the Thymus
(A and B) Thymectomy experiments.
(A) Frequencies (left) and numbers (right) of Foxp3+ T cells in tissues of 25-week-old B6 mice thymectomized or sham operated.
(B) Frequencies (top) and numbers (bottom) of Gata3+ Tregs in VAT.
(C and D) Punctual ablation of Tregs.
(C) Frequencies (left) and numbers (right) of Foxp3+ T cells in tissues of 25-week-old B6.Foxp3DTR mice and their DTR littermates after DT administration at the
indicated ages.
(D) Frequencies (top) and numbers (bottom) of Gata3+ Tregs in VAT. All experiments: pooled data from two to three independent experiments. Error bars indicate
mean ± SD.population V, most within populations I and II, and a few within
population IV expressed MHCII molecules. The MHCII-express-
ing cells within gate IV were B cells (Figure S2).Figure 3. Micro-Expansions of VAT Treg Clones
(A) Degree of VAT Treg proliferation at steady state. 15- or 30-week-old B6 m
incorporation. Left: representative flow cytometry plots; right: summary data.
(B) VAT Treg cells in cycle. Summary data for Ki67 expression by T cell subsets
(C) Long-term VAT Treg proliferation and turnover. Top: schematic representation
drinkingwater according to the protocol illustrated; BrdU incorporation was asses
or Tconv cells of mice analyzed on the indicated days after introducing BrdU in t
after removal of BrdU from the drinkingwater, expressed as percent of the starting
to each data set; corresponding equations, R2 values, and half-lives are presented
(D) TCR CDR3a and CDR3b sequences for various T cell compartments. Each
frequency of a clone’s repeats. Total frequency of expanded clones is shown at
(E) Quantification of clonal TCR frequencies. Sequences obtained from three to
(F) Correlation between frequency of Foxp3+ Tregs and total frequency of repeat
(G) Length of TCR CDR3a and -b amino-acid sequences.
(H) Length of TCR N-region nucleotide sequences. Error bars indicate mean ± S
CThese findings fit very well with observations made using
confocal microscopy and histocytometry. Confocal analysis
revealed numerous irregularly shaped MHCII-positive APCsice were pulsed for 4 hr with EdU, at which time tissues were analyzed for
of 15- or 30-week-old mice.
of BrdU pulse/chase experiment. 15-week-old B6mice were given BrdU in the
sed by flow cytometry. Bottom left: quantification of BrdU incorporation by Treg
he drinking water. Bottom right: same for mice analyzed on the indicated days
BrdU+Foxp3+ Treg pool on day 0 of chase. An exponential decay line was fitted
. n = 5–7 for each time-point; pooled data from three independent experiments.
pie chart represents a single mouse, and the width of the slice illustrates the
the top right.
six individual mice for each compartment.
ed TCRs in each individual. R2 and p values generated using linear regression.
D.
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Figure 5. VAT Treg Dependence on MHCII Molecules
(A) Summary data for Foxp3 and Gata3 expression by CD4+ T cells in tissues of 20-week-old MHCII-KO mice and their WT littermates.
(B and C) Flow cytometry on VAT MHCII-expressing cells.
(B) Expression by immune (CD45+) versus non-immune (CD45) cells in VAT of >20-week-old MHCII-KOmice (gray shading) and their WT littermates (black line).
(C) By CD11b/c splits of VAT CD45+ cells. Same mice as in (B). To the left of each panel are histograms of MHCII molecule expression by the subsets delineated
on the dot plot. (CI), CD11b+chi MFs (confirmed as F480+); (CII), CD11b+clo MFs and monocytes (the latter confirmed as Ly6c+ and F480+/); (CIII), CD11b+c
eosinophils (confirmed as Siglec-F+); (CIV), CD11bc lymphocytes, NK cells and ILCs (see [C]); (CV), CD11bc+ DCs (confirmed as F480).
(D) VAT was obtained from 16-week-old B6 mice, and whole-mount tissues were stained for CD4 (red), MHCII (blue), CD11b (yellow), and CD11c (purple); Foxp3
expression detected by measuring GFP expression (green); VAT morphology determined via autofluorescence (white). See a second example in Figure S3C.
(E) Foxp3+CD4+ Treg and Foxp3CD4+ Tconv cells were distinguished by histocytometry, as were the indicated CD11b/c splits of APCs.
(F) Similar measurements for Treg proximity to MHCII+ cells (intracellular staining) in mice treated twice, 3 days apart, with anti-MHCII mAb and examined 6 hr
after the second shot. Data pooled from two to three independent experiments in all cases. Error bars indicate mean ± SD.
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scattered throughout VAT, many with a classical dendritic mor-
phology, while there was no clear expression of MHCII mole-
cules by adipocytes; less frequent Foxp3CD4+ and rare
Foxp3+CD4+ T cells were also dispersed through the adipose tis-
sue (Figures S3A and S3B). Higher magnification demonstrated
close association between MHCII+ APCs and certain, but not all,
of the Tconv and Treg cells—sometimes the two types of T cell
were in contact with the same APC (insets of Figures S3A and
S3B). Next, we measured the distance between individual
CD4+ T cells and the closest APC, distinguishing between
Foxp3+ and Foxp3 T cells, and delineating APC subsets ac-
cording to histocytometry of CD11b and CD11c expression
(Figures S4, 5D and S3C). Treg and Tconv cells could both be
found in close contact with CD11b+c+ MFs and CD11bc+
DCs, although in both cases the association with DCs was
closest (Figure 5E). The relevance of these interactions was es-
tablished by their significant reduction in mice treated with an
anti-MHCII mAb for 3 days before sacrifice (Figure 5F).
IL-33 Promotion of VAT Treg Accumulation
The Il1rl1 gene, which encodes ST2, the receptor for the cytokine
interleukin (IL)-33 has a pattern of expression by VAT Treg cells
that parallels that of Pparg (Cipolletta et al., 2012). In addition,
administration of IL-33 to obese mice was reported to improve
both adipose tissue inflammation and systemic insulin resis-
tance, attributed at that time to this cytokine’s ability to promote
polarization of MFs to anM2-like phenotype and to foster the dif-
ferentiation of Th2 cells (Miller et al., 2010). But IL-33 is also
known to serve as a T-cell-inciting alarmin (Bonilla et al., 2012);
so, given its documented expression by adipocytes (Wood
et al., 2009), we hypothesized that Treg cells might accumulate
in VAT in response to IL-33 expression.
Cytofluorometric analysis showed that ST2+ Treg cells were
barely detectable in the spleen at all ages examined (Figures
6A, upper panels, and 6B). Many more visceral-adipose Tregs
displayed ST2, their fractional representation rising with age to
attain close to 90% of VAT Tregs in B6 mice >25 weeks of age
(Figures 6A, lower panels, and 6B). Interestingly, this enrichment
for ST2+ Tregs in VAT depended at least to some degree on
PPARg, as it was less evident in mice bearing a Pparg null muta-
tion specifically in Tregs (Figure 6C).
Since IL-33 is an alarmin, we wondered how its expression
in VAT related to the high number of ST2+ Tregs in VAT.
PCR quantification revealed similar levels of Il33 transcripts in
whole-adipose and spleen tissue of 4- to 6-week-old mice
(Figure 6D). Levels increased significantly in both tissues at 8–
10 weeks of age, when expansion of the VAT Treg population
usually begins in our colony, but decreased over time in adipose
tissue. Il33 transcript levels in VAT and spleen were neither un-
usually high (note lung levels) nor unusually low (note muscle
levels) (Figure 6D).
As it was difficult to visualize IL-33 expression by flow cytom-
etry, we turned to immunohistology to establish which VAT cells
expressed this cytokine. In 24-week-old (unmanipulated) B6
mice, cells expressing IL-33, mostly in the nucleus, were located
primarily at the edges of the visceral adipose mass (Figure 6E).
By far, most of these cells were neither hematopoietic nor endo-
thelial as they did not, except in rare cases, display either CD45
or CD31 (Figures S5A and S5B); neither did they stain for smoothCmuscle actin, which is expressed by some fibroblasts (as well as
other cell lineages) (not shown). However, many of the IL-33-ex-
pressing cells did express cadherin-11 (Figure 6F), suggesting
that they were related to fibroblast reticular cells (Malhotra
et al., 2012). We did not detect any clear differences in mice of
ages ranging from 4 to 24 weeks (not shown).
To assess the role of IL-33/ST2 in VAT Treg cell accumulation
in lean mice, we performed loss- and gain-of-function experi-
ments. 25-week-old B6 mice lacking ST2 had a reduced fraction
and number of VAT, but not splenic, Tregs (Figure 7A). This dif-
ference was even more significant when we focused on bona
fide VAT Tregs expressing Gata3 (Figure 7B). Conversely, two in-
jections of IL-33 into 8-week-old wild-type (WT) B6 mice pro-
voked an impressive expansion of the VAT Treg population, as
their numbers/gm tissue increased more than an order of magni-
tude in just 7 days (Figure 7C, lower panel). The expanded Treg
population was enriched in cells expressing both ST2 and Gata3
(Figure 7D, lower panel), and themajority of ST2 expressers were
in cycle, evidenced by co-expression of Ki67 (Figure 7E, lower
panel). The Treg population in the spleen also expanded in
response to IL-33—and expressed ST2, Gata3, and Ki67 more
often than splenic Tregs from PBS-injected littermates did—
but the differences were far less striking than for VAT Tregs (Fig-
ures 7C–7E, upper panels). Similarly, IL-33 had a relatively minor
effect on Tregs in subcutaneous adipose tissue, the inguinal
depot (Figure S6).
That most ST2+ Tregs in the adipose compartment (>75%)
were in cycle argued for population expansion as a major
contributor at this stage, rather than influx of cells from other or-
gans. The expansion abated over time, although a significantly
elevated fraction and number of VAT Tregs was still evident
4 weeks after IL-33 injection (Figure 7F). Interestingly, IL-33
induction of Treg expression in neither the spleen nor VAT
depended on TCR-Ag/MHCII interactions as anti-MHCII mAb
blockade had no detectable effect (Figure 7G).
DISCUSSION
The overall goal of this series of experiments was to elucidate
the means by which Treg cells accumulate in VAT as lean
mice age. Our results argue that the VAT Treg compartment is
seeded from thymocytes generated during the first weeks of
life and noticeably expands after week 10 as a result of indolent
Treg proliferation, of certain clones in particular, coupled with
enhanced survival. Here, we have identified Ag/MHCII and IL-
33 as drivers of VAT Treg accumulation in lean mice. We previ-
ously reported that PPARg agonists promote VAT Treg survival
in the lean state (Cipolletta et al., 2012). How do these various
factors interplay?
Ag/MHC: Retaining Tregs within VAT
Retention of T cells within non-lymphoid tissues generally de-
pends on local recognition of cognate Ag presented by MHC
molecules displayed on the surface of APCs. That Tregs were
retained in epididymal adipose tissue through recognition of
cognate Ag/MHC molecules was indicated by their striking
clonal expansion at that site in mice with a normal repertoire of
TCRs (Figure 3), as well as by our prior documentation ofmultiple
clones with the same CDR3-a amino acid sequence specified byell Metabolism 21, 543–557, April 7, 2015 ª2015 Elsevier Inc. 551
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Figure 6. ST2 and IL-33 Expression in VAT
(A–C) ST2 expression.
(A) Representative cytofluorimetric dot plots of ST2 expression in Tregs of B6. Numbers refer to % CD4+ cells.
(legend continued on next page)
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different nucleotide sequences in mice with an artificially
restricted TCR repertoire (Feuerer et al., 2009).
The relevant class of MHCmolecules was MHCII, specifically
the AaAb dimer, given that EaEb is absent from B6 mice.
Indeed, we found a preponderance of MHCII+ CD11b+c+ MFs
and some MHCII+ CD11bc+ DCs in epididymal adipose tissue
and observed Tregs in close association with both subsets,
which was dependent on expression of MHCII molecules. Our
findings are consistent with a report highlighting the importance
of MHCII+ MFs in the stimulation of VAT Tconv cells (Morris
et al., 2013), but do not support previous contentions that
MHCII molecule expression on adipocytes is key to VAT Tconv
cell activation (Deng et al., 2013). We did not expressly examine
expression of MHCII molecules on innate lymphoid cells (ILCs)
in VAT, a cell-type reported to display these molecules in other
contexts, but given the few MHCII+ cells falling within the rele-
vant gate (Figure S2), they would have to be rare, at least in ag-
ing lean mice. The identity of the culprit Ag(s) is unknown at this
time.
PPARg: Molding the Treg Phenotype for Survival in VAT
We previously established that the accumulation and phenotype
of VAT Treg cells depend critically on PPARg, the ‘‘master regu-
lator’’ of adipocyte differentiation and function (Cipolletta et al.,
2012). Retroviral transduction experiments showed that PPARg
controls expression of the transcripts distinguishing adipose tis-
sue from lymphoid-organ Tregs, notably a set of transcripts en-
coding proteins involved in lipid metabolism and likely critical for
Treg survival in a lipid-rich environment. Indeed, injection of a
PPARg antagonist into lean mice provoked rapid disintegration
of the VAT Treg phenotype, compromising their survival (Cipol-
letta et al., 2012).
We do not know yet whether VAT Tregs emerge from the
thymus with their characteristic transcriptome already fixed or,
alternatively, whether they arrive in the adipose tissue looking
and acting like lymphoid tissue Tregs and eventually adopt a
bona fide VAT Treg phenotype in response to local cues. The
absence of anti-PPARg mAbs compatible with cytofluorometric
analysis renders this issue difficult to address at present. How-
ever, we suspect that the answer lies somewhere between these
two possibilities. We do detect Pparg gene transcripts at low
levels in the circulating Tregs of lymphoid organs; so it is possible
that a PPARg-expressing VAT Treg precursor is generated in the
thymus, either a rare one expressing low levels of PPARg or an
extremely rare one making substantial levels. The precursor
could emerge from the thymus; circulate through the lymphoid
organs; and, eventually, if it expresses the correct TCR, be re-
tained in VAT, where PPARg ligands and other local mediators
could confirm and lock in the VAT Treg phenotype.(B) Quantification of percent Tregs (right y axis) and percent Tregs displaying S
periments.
(C). Summary data on Treg expression of ST2 in VAT and LN of 20-week-old mice
(D–F) IL-33 expression.
(D) PCR quantification of IL-33 transcript levels for various tissues from mice of d
(E) Immunohistology on VAT tissue of 24-week-old B6 mice stained for IL-33 or/
panel illustrates nuclear staining of IL-33.
(F) Immunohistology on the same tissues, stained for IL-33 or/and Cadherin-11.
mean ± SD.
CIL-33: Expanding the VAT Treg Compartment with Aging
IL-33, amember of the IL-1 family of cytokines, is garneringmore
and more attention (Garlanda et al., 2013). Secreted mostly by
stromal and parenchymal cells, such as epithelial and endothe-
lial cells, it is best known for promoting type-2 immunity through
actions on type-2 ILCs, T helper (Th)2 cells, and anti-inflamma-
tory MFs. It can also act as an alarmin, released by necrotic cells
to report on recent or impending tissue damage (e.g., hypoxia or
mechanical stress). Most recently, attention has turned to IL-33’s
ability to expand Treg populations, both in lymphoid organs
(Turnquist et al., 2011; Schiering et al., 2014) and in the colonic
lamina propria (Schiering et al., 2014).
IL-33 and its receptor ST2 were found to be expressed in hu-
man adipose tissue (Wood et al., 2009). Moreover, injection of IL-
33 into HFD-fedmice reduced adiposity, inflammation, and insu-
lin resistance (Miller et al., 2010). These effects were attributed to
IL-33’s ability to promote Th2 responses and polarization of MFs
toward an anti-inflammatory phenotype. However, interpretation
of these findings was confounded by the influence of IL-33 on
adiposity under the long-term experimental conditions em-
ployed, raising the question of whether the effects on inflamma-
tionmight only be secondary. A later study on the impact of IL-33
in VAT highlighted a pathway encompassing ILCs, eosinophils,
and anti-inflammatory MFs (Molofsky et al., 2013).
Given the above-cited results and the fact that Il1rl1 tran-
scripts were among those most differentially expressed in
VAT versus lymphoid tissue Tregs (Cipolletta et al., 2012), we
explored the hypothesis that IL-33 might be an important driver
of Treg accumulation in the epididymal depot of aging lean
mice. Results from both gain- and loss-of-function experiments
supported this notion. While, under our conditions, IL-33 injec-
tion expanded the Treg compartments in both lymphoid tissues
(as anticipated from published data (Turnquist et al., 2011;
Schiering et al., 2014) and VAT (without significantly impacting
body or fat weight), the increase was more than an order of
magnitude greater at the adipose site. This was a long-lasting
effect as even a month after IL-33 injection VAT Tregs were
significantly over-represented. The fraction of VAT Tregs ex-
pressing ST2 was impressively high, although, per gram tissue,
VAT expressed IL-33 transcripts at levels quite similar to those
of spleen. It is possible that the form of IL-33 differs at the
two sites: nuclear versus secreted, differentially cleaved or
otherwise post-translationally modified, bound to soluble ST2
or not, etc. Or it may be that the greater response of VAT
Tregs reflects aspects of their distinct phenotype; for example,
their frequent expression of ST2. The latter explanation
seemsmore easy to reconcile with the fact that a striking adipo-
se:lymphoid tissue differential is seen after injection of IL-33
exogenously.T2 (left y axis). n = 4–9 for each age; data pooled from two independent ex-
lacking PPARg specifically on Tregs (Treg-Ppargmut) and their WT littermates.
iverse ages.
and by DAPI, Magnification, 203. Higher-magnification (603) inset in the right
Magnification = 403. Arrows indicate doubly stained cells. Error bars indicate
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Figure 7. IL-33 Promotion of VAT Treg Accumulation
(A and B) Loss-of-function: ST2-KO.
(A) Representative dot plots (left panels) and summary quantification of frequencies (center panels) and numbers (right panels) of Foxp3+ Tregs in 25-week-old
ST2-KO and -WT littermates.
(legend continued on next page)
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At present, we cannot say to what extent the effects of
increasing or decreasing ST2 signaling on the VAT Treg
compartment are direct or require additional ‘‘helper’’ leukocyte
populations. We can, however, say that the phenotype of the
Tregs expanded in epididymal adipose tissue by IL-33 injection
is typical of VAT Tregs. Interestingly, Il1rl1 is a member of a clus-
ter of genes co-regulated with Pparg in a set of metabolically
relevant Treg data sets (Cipolletta et al., 2012), the VAT Treg
population is reduced in mice lacking PPARg specifically in
Tregs (Cipolletta et al., 2012), and few of the remaining ones
express St2 on their surface (Figure 6C), together suggesting a
link between these two receptor pathways. Thus, as bona fide
VAT Tregs emerge in adipose tissue, they may be sensitive to
IL-33, whose concentration and/or form may respond to stress
signals in the expanding fat pad (e.g., hypoxia or mechanical
stretching).
This study has focused on factors driving accumulation of
the unique Treg compartment in VAT of lean mice as they age.
How these factors are inhibited or evaded in the development
of obesity-induced inflammation and metabolic dysregulation
is an important topic for future studies. Learning how these
factors operate and interplay might expand therapeutic options
for addressing the growing world-wide problem of metabolic
irregularities.
EXPERIMENTAL PROCEDURES
Mice
Males of the specified ages were employed, all bred in our specific-pathogen-
free facilities at Harvard Medical School. Experiments were conducted
according to protocols approved by Harvard Medical School’s Institutional
Animal Care and Use Committee (HMS protocol #02954). Details concerning
the various mouse lines used and their breeding can be found in the Supple-
mental Experimental Procedures.
Mouse Manipulations
Details of cell isolation and flow cytometry can be found in the Supplemental
Experimental Procedures. For the Treg conversion and migration studies,
5 3 106 Foxp3CD4+ Tconv cells or 1 3 106 Foxp3+CD4+ Treg cells were
sorted from pooled spleen and LNs of 6- to 8-week-old CD45.1 Foxp3iGFP
donor mice, and were iv transferred into 20-week-old Foxp3iGFPCD45.2 recip-
ient mice. Recipients were sacrificed 4 weeks after transfer; LNs, spleen, and
epididymal fat pads were removed, dispersed, and analyzed by flow
cytometry.
Photoconversion of CLN cells in Kaede/B6 mice was performed as previ-
ously described (Morton et al., 2014). Briefly, 16- or 24-week-old Kaede/B6
mice were anesthetized with ketamine/xylazine in combination (10 mg/kg/
2mg/kg ip). The fur attached to the skin covering the CLNs was removed using
depilatory cream, applied for 2 min. Mice were placed on their back, with an
aluminum foil blanket covering all but the depilated area, and violet light
(Electra Pro Series 405 nm Violet Handheld Laser, Laserglow Technologies)
was shone onto the exposed area for a period of 3.5 min, the pre-established
time for effective but innocuous photoconversion at this anatomical site. In or-
der to manipulate the size of the light field (beam diameter: 3.5 mm) so that
both CLNs could be exposed, we attached a lens to the laser to de-focus(B) Same except frequencies of Gata3+Foxp3+ T cells within the CD4+ compartm
(C–G) Gain-of-function: IL-33 administration.
(C and D) As per (A) except 8-week-old B6 mice were ip injected with 2 mg of IL-
(E) T cells from the same mice were stained for Ki67. Left: representative dot plo
(F) Mice treated with IL-33 as per (C) but were followed for longer times. Fraction
(G) Mice treated with IL-33 and anti-MHCII mAb and analyzed as schematized. Fra
from at least two independent experiments. Error bars indicate mean ± SD.
Cthe beam, and the source of the de-focused light beam was positioned
28 cm above the mouse.
Parabiotic pairs were generated as previously described (Wagers et al.,
2002) by joining male mice from CD45.1 versus CD45.2 congenic strains.
Matched male 8-week-old CD45.1 and CD45.2 congenic mice were anesthe-
tized with 2.5% avertin (15 ml per g of body weight) and were shaved along
opposite lateral flanks. Skin was wiped with alcohol prep pads and further
cleaned with Betadine solution and 70% isopropyl alcohol. Mirrored incisions
were made on lateral aspects of the two mice, and sutures were placed
through the olecranon and knee joints to secure the legs. Ventral and dorsal
skin flaps were then approximated by staples and suture to conjoin the
mice. Mice were taken 4 or 6 weeks after conjoinment for flow cytometric anal-
ysis of chimerism of different lymphoid cell compartments using CD45.1
versus CD45.2 distinction.
For monitoring of cell division and turnover, 1 mg EdU was iv injected into
15- or >25-week-old B6 mice, and 4 hr later, cells were processed for detec-
tion by the Click-iT EdU kit following the manufacturer’s (Molecular Probes) in-
structions. BrdU powder (Sigma) was added to the drinking water (0.8 mg/ml)
and protected from the light; BrdU-containing water was changed every
2 days. Cells were processed for analysis and stained for BrdU detection at
various times following the manufacturer’s instructions (BD Biosciences). A
more precise protocol can be found in Figure 3C and its legend.
For thymectomies, mice of the designated ages were anesthetized with ke-
tamine/xylazine in combination (10 mg/kg/2 mg/kg ip). The fur attached to the
skin covering the thymus was removed using depilatory cream, applied for
2 min. An incision was made cutting the first three ribs, and the thymus was
excised using forceps. The skin was closed and secured with two to three sur-
gical clips.
For ablating Tregs, Foxp3DTR mice and DTR-negative littermates of the
designated ages were ip injected with DT (Sigma) at 10 ng/g body weight for
2 consecutive days. Mice were aged to 25 weeks old, and lymphoid organs
and VAT were analyzed by flow cytometry.
To expand Tregs, mice were ip injected with recombinant IL-33 (Biolegend)
at 2 mg per injection every 3 days for one week prior to analysis. In some exper-
iments, MHCII molecules were blocked by ip injection of themAbM5/114 (Bio-
XCell), as per the scheme in Figure 7G.
TCR Analysis
Single Treg or Tconv cells were sorted from VAT or LN into 96-well plates.
CDR3a and b sequenceswere obtained using primer mixes covering all known
chains. Extreme care was taken to avoid contamination. See further details in
the Supplemental Experimental Procedures.
Imaging of VAT Cells and Histology of IL-33 Producers
VAT was isolated and fixed with 0.05 M phosphate buffer containing 0.1 M L-
lysine, 2 mg/ml NaIO4, and 10 mg/ml paraformaldehyde for 18 hr at 4
C and
was then equilibrated in 30% sucrose solution overnight. Tissues were frozen
in OCT and stored at 80C. Whole-mount tissue samples were then blocked
for 4 hr in phosphate buffer with 1%normalmouse serum, 1%bovine serumal-
bumin, and 0.3%Triton X-100. Tissueswere stained for 18 hr at 4C in the pres-
ence of CD11b-BV420, F4-80eF450 (eBioscience), CD4-BV510, Foxp3-GFP,
CD3-PE,CD11c-AF647, andMHCII-AF700. Imagingwas conductedon a Leica
SP8confocalmicroscopewithamotorizedstage for image tiling, equippedwith
a 1.2 NA 403 oil emersion objective, with an additional optical zoom of 1.53.
Tiled images composed of 5 3 5 z stacks of 30–50 mm each were compiled
and used for final imaging analysis. Histocytometric subset identification was
performed using the Imaris (Bitplane) surface creation utility. T cells were iden-
tified as CD3+MHCII, and APCs were identified as CD3MHCII+. Cells wereent were examined.
33 twice, 3 days apart, and were analyzed 3 days later.
ts; right: summary data.
(left) and number (right) of Tregs in spleen (top) or VAT (bottom).
ction (left) and number (right) of Tregs in spleen (top) and VAT (bottom). Pooled
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then further subsetted by expression of CD4 and Foxp3 for T cells and CD11b,
CD11c, andF4-80 for APCs. Amore in-depth description of the histocytometric
technique can be found in Gerner et al. (2012).
For IL-33 staining, VAT tissues were fixed and frozen in OCT as described
above and then sectioned at a thickness of 50 mm. Tissues were then permea-
bilized with 0.3% Triton X-100 in PBS for 5 min and blocked with 5% fetal
bovine serum and 10% donkey serum in PBS at room temperature for 1 hr.
Tissues were stained for 2 hr at room temperature in the presence of goat
anti-IL-33 (R&D) and mouse anti-Cadherin 11 (Invitrogen), followed by staining
for 1 hr at room temperature with Cy3-donkey anti-goat secondary antibody,
Cy5-donkey anti-mouse secondary antibody (Jackson Laboratory), CD45-
APC, CD31-Alexa Fluor 647 (Biolegend), or anti-SMA-FITC (Sigma-Aldrich).
Tissue sections were further stained with DAPI for 5 min before imaging. Imag-
ing was conducted on an Olympus FluoView confocal microscope with 203
and 403 objectives.
Statistical Analyses
Data were routinely presented as mean ± SD. Unless stated otherwise: signif-
icance was assessed by the Student’s t test or ANOVA using Prism 5 (Graph-
Pad Software; p = *, < 0.05; **, < 0.01; ***, < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/10.
1016/j.cmet.2015.03.005.
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